Oral Absorption Basics: Pathways, Physico-chemical and Biological Factors Affecting Absorption

Developing Solid Oral Dosage Forms

Volumn , Issue , 2009, Pages

  Liu, Zhongqiu ^a   Wang, Stephen ^b   Hu, Ming ^c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Schering Plough ^*  (United States)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882827324     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-444-53242-8.00011-4     Document Type: Chapter

References (111)

1. Hwang S.J., Park H., Park K. Gastric retentive drug-delivery systems. Critical Reviews in Therapeutic Drug Carrier Systems 1998, 15(3):243-284.
2. Jeong E.J., Liu X., Jia X., Chen J., Hu M. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Current Drug Metabolism 2005, 6(5):455-468.
3. Hu M., Cheng Z., Zheng L. Functional and molecular characterization of rat intestinal prolidase. Pediatric Research 2003, 53(6):905-914.
4. Johnson B.M., Zhang P., Schuetz J.D., Brouwer K.L. Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug metabolism and disposition: The biological fate of chemicals 2006, 34(4):556-562.
5. Klaassen C.D., Slitt A.L. Regulation of hepatic transporters by xenobiotic receptors. Current Drug Metabolism 2005, 6(4):309-328.
6. Fix J.A., Engle K., Porter P.A., Leppert P.S., Selk S.J., Gardner C.R., Alexander J. Acylcarnitines: drug absorption-enhancing agents in the gastrointestinal tract. The American Journal of Physiology 1986, 251(3 Pt 1):G332-340.
7. Nellans H.N. (B) Mechanisms of peptide and protein absorption (1) Paracellular intestinal transport: Modulation of absorption. Advanced Drug Delivery Reviews 1991, 7(3):339-364.
8. Lee V.H.L., Akira Y. Penetration and enzymatic barriers to peptide and protein absorption. Advanced Drug Delivery Reviews 1989, 4(2):171-207.
9. Collington G.K., Hunter J., Allen C.N., Simmons N.L., Hirst B.H. Polarized efflux of 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein from cultured epithelial cell monolayers. Biochemical Pharmacology 1992, 44(3):417-424.
10. Inui K., Yamamoto M., Saito H. Transepithelial transport of oral cephalosporins by monolayers of intestinal epithelial cell line Caco-2: specific transport systems in apical and basolateral membranes. The Journal of Pharmacology and Experimental Therapeutics 1992, 261(1):195-201.
11. Hidalgo I.J., Ryan F.M., Marks G.J., Smith P.L. pH-dependent transepithelial transport of cephalexin in rabbit intestinal mucosa. International Journal of Pharmacy 1993, 98:83-92.
12. Caroline H., Gochoco F.M.R., Miller J., Smith P.L., Hidalgo I.J. Uptake and transepithelial transport of the orally absorbed cephalosporin cephalexin, in the human intestinal cell line, Caco-2. International Journal of Pharmaceutics 1994, 104(3):187-202.
13. Hu M., Amidon G.L. Passive and carrier-mediated intestinal absorption components of captopril. Journal of Pharmaceutical Sciences 1988, 77(12):1007-1011.
14. Dantzig A.H., Bergin L. Carrier-mediated uptake of cephalexin in human intestinal cells. Biochemical and Biophysical Research Communications 1988, 155(2):1082-1087.
15. Dantzig A.H., Duckworth D.C., Tabas L.B. Transport mechanisms responsible for the absorption of loracarbef, cefixime, and cefuroxime axetil into human intestinal Caco-2 cells. Biochimica et Biophysica Acta 1994, 1191(1):7-13.
16. Yang C.Y., Dantzig A.H., Pidgeon C. Intestinal peptide transport systems and oral drug availability. Pharmaceutical Research 1999, 16(9):1331-1343.
17. Ganapathy V., Leibach F.H. Role of pH gradient and membrane potential in dipeptide transport in intestinal and renal brush-border membrane vesicles from the rabbit. Studies with l-carnosine and glycyl-l-proline. The Journal of Biological Chemistry 1983, 258(23):14189-14192.
18. Fei Y.J., Sugawara M., Liu J.C., Li H.W., Ganapathy V., Ganapathy M.E., Leibach F.H. cDNA structure, genomic organization, and promoter analysis of the mouse intestinal peptide transporter PEPT1. Biochimica et Biophysica Acta 2000, 1492(1):145-154.
19. Liang R., Fei Y.J., Prasad P.D., Ramamoorthy S., Han H., Yang-Feng T.L., Hediger M.A., Ganapathy V., Leibach F.H. Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization. The Journal of Biological Chemistry 1995, 270(12):6456-6463.
20. Saito H., Okuda M., Terada T., Sasaki S., Inui K. Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney. The Journal of Pharmacology and Experimental Therapeutics 1995, 275(3):1631-1637.
21. Boll, M., Herget, M., Wagener, M., Weber, W. M., Markovich, D., Biber, J., Clauss, W., Murer, H. & Daniel, H. (1996). Expression cloning and functional characterization of the kidney cortex high-affinity proton-coupled peptide transporter. Proceedings of the National Academy of Sciences of the United States of America, 93(1), 284-289.
22. Ogihara H., Saito H., Shin B.C., Terado T., Takenoshita S., Nagamachi Y., Inui K., Takata K. Immuno-localization of H+/peptide cotransporter in rat digestive tract. Biochemical and Biophysical Research Communications 1996, 220(3):848-852.
23. Rubio-Aliaga I., Boll M., Daniel H. Cloning and characterization of the gene encoding the mouse peptide transporter PEPT2. Biochemical and Biophysical Research Communications 2000, 276(2):734-741.
24. Ramamoorthy S., Liu W., Ma Y.Y., Yang-Feng T.L., Ganapathy V., Leibach F.H. Proton/peptide cotransporter (PEPT 2) from human kidney: functional characterization and chromosomal localization. Biochimica et Biophysica Acta 1995, 1240(1):1-4.
25. Terada T., Inui K. Peptide transporters: Structure, function, regulation and application for drug delivery. Current Drug Metabolism 2004, 5(1):85-94.
26. Terada T., Sawada K., Ito T., Saito H., Hashimoto Y., Inui K. Functional expression of novel peptide transporter in renal basolateral membranes. American Journal of Physiology. Renal physiology 2000, 279(5):F851-857.
27. Sawada K., Terada T., Saito H., Inui K. Distinct transport characteristics of basolateral peptide transporters between MDCK and Caco-2 cells. Pflügers Archiv: European Journal of Physiology 2001, 443(1):31-37.
28. Hu M., Subramanian P., Mosberg H.I., Amidon G.L. Use of the peptide carrier system to improve the intestinal absorption of l-alpha-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of l-alpha-methyldopa. Pharmaceutical Research 1989, 6(1):66-70.
29. Nakanishi T., Tamai I., Sai Y., Sasaki T., Tsuji A. Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. Cancer Research 1997, 57(18):4118-4122.
30. Mann G.E., Yudilevich D.L., Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiological Reviews 2003, 83(1):183-252.
31. Qian X., Vinnakota S., Edwards C., Sarkar H.K. Molecular characterization of taurine transport in bovine aortic endothelial cells. Biochimica et Biophysica Acta 2000, 1509(1-2):324-334.
32. Deves R., Boyd C.A. Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiological Reviews 1998, 78(2):487-545.
33. Cheeseman C. Role of intestinal basolateral membrane in absorption of nutrients. The American Journal of Physiology 1992, 263(3 Pt 2):R482-488.
34. Cheeseman C.I. Characteristics of lysine transport across the serosal pole of the anuran small intestine. Journal of Physiology 1983, 338:87-97.
35. Hammerman M.R. Na+-independent l-arginine transport in rabbit renal brush border membrane vesicles. Biochimica et Biophysica Acta 1982, 685(1):71-77.
36. Hilden S.A., Sacktor B. l-arginine uptake into renal brush border membrane vesicles. Archives of Biochemistry and Biophysics 1981, 210(1):289-297.
37. Stieger B., Stange G., Biber J., Murer H. Transport of l-lysine by rat renal brush border membrane vesicles. Pflügers Archiv: European Journal of Physiology 1983, 397(2):106-113.
38. You G. The role of organic ion transporters in drug disposition: an update. Current Drug Metabolism 2004, 5(1):55-62.
39. Pritchard J.B., Miller D.S. Mechanisms mediating renal secretion of organic anions and cations. Physiological Reviews 1993, 73(4):765-796.
40. Sweet D.H., Pritchard J.B. The molecular biology of renal organic anion and organic cation transporters. Cell Biochemistry and Biophysics 1999, 31(1):89-118.
41. Koepsell H., Gorboulev V., Arndt P. Molecular pharmacology of organic cation transporters in kidney. The Journal of Membrane Biology 1999, 167(2):103-117.
42. Tamai I., Yabuuchi H., Nezu J., Sai Y., Oku A., Shimane M., Tsuji A. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Letters 1997, 419(1):107-111.
43. Wu X., George R.L., Huang W., Wang H., Conway S.J., Leibach F.H., Ganapathy V. Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochimica et Biophysica Acta 2000, 1466(1-2):315-327.
44. Tamai I., Ohashi R., Nezu J.I., Sai Y., Kobayashi D., Oku A., Shimane M., Tsuji A. Molecular and functional characterization of organic cation/carnitine transporter family in mice. The Journal of Biological Chemistry 2000, 275(51):40064-40072.
45. Wu X., Huang W., Prasad P.D., Seth P., Rajan D.P., Leibach F.H., Chen J., Conway S.J., Ganapathy V. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. The Journal of Pharmacology and Experimental Therapeutics 1999, 290(3):1482-1492.
46. Wu X., Prasad P.D., Leibach F.H., Ganapathy V. cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochemical and Biophysical Research Communications 1998, 246(3):589-595.
47. Wagner C.A., Lukewille U., Kaltenbach S., Moschen I., Broer A., Risler T., Broer S., Lang F. Functional and pharmacological characterization of human Na(+)-carnitine cotransporter hOCTN2. American Journal of Physiology. Renal Physiology, 2000, 279(3):F584-591.
48. Cattori V., van Montfoort J.E., Stieger B., Landmann L., Meijer D.K., Winterhalter K.H., Meier P.J., Hagenbuch B. Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflügers Archiv: European Journal of Physiology 2001, 443(2):188-195.
49. Gao B., Hagenbuch B., Kullak-Ublick G.A., Benke D., Aguzzi A., Meier P.J. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. The Journal of Pharmacology and Experimental Therapeutics 2000, 294(1):73-79.
50. Kullak-Ublick G.A., Ismair M.G., Stieger B., Landmann L., Huber R., Pizzagalli F., Fattinger K., Meier P.J., Hagenbuch B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001, 120(2):525-533.
51. Nozawa T., Tamai I., Sai Y., Nezu J., Tsuji A. Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin. The Journal of Pharmacy and Pharmacology 2003, 55(7):1013-1020.
52. Lee W., Glaeser H., Smith L.H., Roberts R.L., Moeckel G.W., Gervasini G., Leake B.F., Kim R.B. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): Implications for altered drug disposition and central nervous system drug entry. The Journal of Biological Chemistry 2005, 280(10):9610-9617.
53. Reichel C., Gao B., Van Montfoort J., Cattori V., Rahner C., Hagenbuch B., Stieger B., Kamisako T., Meier P.J. Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver. Gastroenterology 1999, 117(3):688-695.
54. Konig J., Cui Y., Nies A.T., Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. The Journal of Biological Chemistry 2000, 275(30):23161-23168.
55. Konig J., Cui Y., Nies A.T., Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. American Journal of Physiology. Gastrointestinal and Liver Physiology 2000, 278(1):G156-164.
56. Kong W., Engel K., Wang J. Mammalian nucleoside transporters. Current Drug Metabolism 2004, 5(1):63-84.
57. Griffith D.A., Jarvis S.M. Nucleoside and nucleobase transport systems of mammalian cells. Biochimica et Biophysica Acta 1996, 1286(3):153-181.
58. Cabrita M.A., Baldwin S.A., Young J.D., Cass C.E. Molecular biology and regulation of nucleoside and nucleobase transporter proteins in eukaryotes and prokaryotes. Biochemistry and Cell Biology (Biochimie et Biologie Cellulaire) 2002, 80(5):623-638.
59. Sue Masters B., Marohnic C.C. Cytochromes P450-a family of proteins and scientists-understanding their relationships. Drug Metabolism Reviews 2006, 38(1-2):209-225.
60. Jakoby W.B. Detoxication and Drug Metabolism: Conjugation and Related Systems 1981, Academic Press, New York, xxii.
61. Testa B., Jenner P. Drug Metabolism: Chemical and Biochemical Aspects 1976, Marcel Dekker, New York, p. xiii.
62. Numa S.O. Fatty Acid Metabolism and its Regulation 1984, Elsevier, Amsterdam New York, p. xi.
63. Liu Y., Hu M. Absorption and metabolism of flavonoids in the caco-2 cell culture model and a perused rat intestinal model. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2002, 30(4):370-377.
64. Liu Y., Liu Y., Dai Y., Xun L., Hu M. Enteric disposition and recycling of flavonoids and ginkgo flavonoids. Journal of Alternative and Complementary Medicine 2003, 9(5):631-640.
65. Conley A., Hinshelwood M. Mammalian aromatases. Reproduction 2001, 121(5):685-695.
66. Fisher M.B., Campanale K., Ackermann B.L., VandenBranden M., Wrighton S.A. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2000, 28(5):366-560.
67. Guengerich F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. The AAPS Journal 2006, 8(1):E101-111.
68. Dervieux T., Meshkin B., Neri B. Pharmacogenetic testing: Proofs of principle and pharmacoeconomic implications. Mutation Research 2005, 573(1-2):180-194.
69. Bischoff S.C. Food allergies. Current Gastroenterology Reports 2006, 8(5):374-382.
70. Chen J., Lin H., Hu M. Metabolism of flavonoids via enteric recycling: Role of intestinal disposition. The Journal of Pharmacology and Experimental Therapeutics 2003, 304(3):1228-1235.
71. Hu M., Krausz K., Chen J., Ge X., Li J., Gelboin H.L., Gonzalez F.J. Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2003, 31(7):924-931.
72. Wang S.W., Chen J., Jia X., Tam V.H., Hu M. Disposition of flavonoids via enteric recycling: Structural effects and lack of correlations between in vitro and in situ metabolic properties. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2006.
73. Mackenzie P.I., Walter Bock K., Burchell B., Guillemette C., Ikushiro S., Iyanagi T., Miners J.O., Owens I.S., Nebert D.W. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005, 15(10):677-685.
74. Burchell B., Brierley C.H., Rance D. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Science 1995, 57(20):1819-1831.
75. Gamage N., Barnett A., Hempel N., Duggleby R.G., Windmill K.F., Martin J.L., McManus M.E. Human sulfotransferases and their role in chemical metabolism. Toxicological Sciences: An Official Journal of The Society of Toxicology 2006, 90(1):5-22.
76. Nimmagadda D., Cherala G., Ghatta S. Cytosolic sulfotransferases. Indian Journal of Experimental Biology 2006, 44(3):171-182.
77. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2004, 32(12):1377-1382.
78. Coles B.F., Kadlubar F.F. Detoxification of electrophilic compounds by glutathione S-transferase catalysis: Determinants of individual response to chemical carcinogens and chemotherapeutic drugs?. Biofactors 2003, 17(1-4):115-130.
79. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annual Review of Pharmacology and Toxicology 2005, 45:51-88.
80. Haga S.B., Thummel K.E., Burke W. Adding pharmacogenetics information to drug labels: Lessons learned. Pharmacogenet Genomics 2006, 16(12):847-854.
81. Kessel D., Botterill V., Wodinsky I. Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. Cancer Research 1968, 28(5):938-941.
82. Gottesman M.M., Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Letters 2006, 580(4):998-1009.
83. Hyde S.C., Emsley P., Hartshorn M.J., Mimmack M.M., Gileadi U., Pearce S.R., Gallagher M.P., Gill D.R., Hubbard R.E., Higgins C.F. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 1990, 346(6282):362-365.
84. Evans A.M. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Therapeutic Drug Monitoring 2000, 22(1):131-136.
85. Hunter J., Hirst B.H., Simmons N.L. Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein. British Journal of Cancer 1991, 64(3):437-444.
86. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A., van Deemter L., Smit J.J., van der Valk M.A., Voordouw A.C., Spits H., van Tellingen O., Zijlmans J.M., Fibbe W.E., Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(8):4028-4033.
87. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258(5088):1650-1654.
88. Buchler M., Konig J., Brom M., Kartenbeck J., Spring H., Horie T., Keppler D. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. The Journal of Biological Chemistry 1996, 271(25):15091-15098.
89. Paulusma C.C., Bosma P.J., Zaman G.J., Bakker C.T., Otter M., Scheffer G.L., Scheper R.J., Borst P., Oude Elferink R.P. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996, 271(5252):1126-1128.
90. Belinsky M.G., Kruh G.D. MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver. British Journal of Cancer 1999, 80(9):1342-1349.
91. Stride B.D., Grant C.E., Loe D.W., Hipfner D.R., Cole S.P., Deeley R.G. Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Molecular Pharmacology 1997, 52(3):344-353.
92. de Jong M.C., Slootstra J.W., Scheffer G.L., Schroeijers A.B., Puijk W.C., Dinkelberg R., Kool M., Broxterman H.J., Meloen R.H., Scheper R.J. Peptide transport by the multidrug resistance protein MRP1. Cancer Research 2001, 61(6):2552-2557.
93. Cole S.P., Sparks K.E., Fraser K., Loe D.W., Grant C.E., Wilson G.M., Deeley R.G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Research 1994, 54(22):5902-5910.
94. Kawabe T., Chen Z.S., Wada M., Uchiumi T., Ono M., Akiyama S., Kuwano M. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Letters 1999, 456(2):327-331.
95. Paulusma C.C., Oude Elferink R.P. The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. Journal of Molecular Medicine 1997, 75(6):420-428.
96. Sekine T., Watanabe N., Hosoyamada M., Kanai Y., Endou H. Expression cloning and characterization of a novel multispecific organic anion transporter. The Journal of Biological Chemistry 1997, 272(30):18526-18529.
97. Sweet D.H., Wolff N.A., Pritchard J.B. Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. The Journal of Biological Chemistry 1997, 272(48):30088-30095.
98. Moller J.V., Sheikh M.I. Renal organic anion transport system: pharmacological, physiological, and biochemical aspects. Pharmacological Reviews 1982, 34(4):315-358.
99. Sweet D.H., Bush K.T., Nigam S.K. The organic anion transporter family: from physiology to ontogeny and the clinic. American Journal of Physiology. Renal Physiology 2001, 281(2):F197-205.
100. Deguchi T., Kusuhara H., Takadate A., Endou H., Otagiri M., Sugiyama Y. Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney International 2004, 65(1):162-174.
101. Benet L.Z., Cummins C.L., Wu C.Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. International Journal of Pharmaceutics 2004, 277(1-2):3-9.
102. Cummins C.L., Jacobsen W., Benet L.Z. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. The Journal of Pharmacology and Experimental Therapeutics 2002, 300(3):1036-1045.
103. 14C] genistein in the rat; plasma pharmacokinetics of parent compound, genistein glucuronide and total radioactivity. European Journal of Drug Metabolism and Pharmacokinetics 2002, 27(4):249-258.
104. Setchell K.D., Brown N.M., Desai P.B., Zimmer-Nechimias L., Wolfe B., Jakate A.S., Creutzinger V., Heubi J.E. Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. The Journal of Nutrition 2003, 133(4):1027-1035.
105. Lipinski C.A. Chris Lipinski discusses life and chemistry after the Rule of Five. Drug Discovery Today 2003, 8(1):12-16.
106. Remko M., Swart M., Bickelhaupt F.M. Theoretical study of structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some centrally acting antihypertensives. Bioorganic & Medicinal Chemistry 2006, 14(6):1715-1728.
107. Wenlock M.C., Austin R.P., Barton P., Davis A.M., Leeson P.D. A comparison of physiochemical property profiles of development and marketed oral drugs. Journal of Medicinal Chemistry 2003, 46(7):1250-1256.
108. Aulton M.E., Cooper J.W. Pharmaceutics: The Science of Dosage Form Design 1988, Churchill Livingstone, Edinburgh, New York, p. xv, p. 734. 1st edn.
109. Kimura T., Higaki K. Gastrointestinal transit and drug absorption. Biological & Pharmaceutical Bulletin 2002, 25(2):149-164.
110. Shargel L., Wu-Pong S., Yu A.B.C. Applied Biopharmaceutics & Pharmacokinetics 2005, McGraw-Hill, Medical Pub., Division, New York, p. xx, p. 892. 5th edn.
111. Ritschel W.A., Kearns G.L. American Pharmaceutical Association. In:. Handbook of Basic Pharmacokinetics-Including Clinical Applications 2004, xii.. American Pharmacists Association, Washington, DC. 6th edn.